

2. Andrioli J, Andrade C, Souza C, Lima Z, Haun M, Cazorla I, et al. Frequency of yeast in vaginal fluid of women with and without clinical suspicion of vulvovaginal candidiasis. *Rev Bras Ginecol Obstet.* 2009;31:300–4.
3. Darce M, González A, Barnabe C, Larrouy G. First characterization of *Candida albicans* by random amplified polymorphic DNA method in Nicaragua and comparison of the diagnosis methods for vaginal candidiasis in Nicaraguan women. *Mem Inst Oswaldo Cruz.* 2000;97:985–9.
4. García M, García S, Copolillo E, Cora M, Barata A, Vay C, et al. Prevalencia de candidiasis vaginal en embarazadas. Identificación de levaduras y sensibilidad a los antifúngicos. *Rev Argent Microbiol.* 2006;38:9–12.
5. Ilkit M, Guzel AB. The epidemiology, pathogenesis, and diagnosis of vulvovaginal candidosis: A mycological perspective. *Crit Rev Microbiol.* 2011;37:250–61.
6. Rivera R, Flores R, Arriaga M. Identificación de especies de *Candida* causantes de vaginitis en la población mexicana. *Enferm Infect Microbiol Clin.* 2006;24:634–6.
7. Sobel J. Vulvovaginal candidosis. *Lancet.* 2007;369:1961–71.

Rosa Moreno y William Morales\*

Departamento de Microbiología, Escuela de Bioanálisis Clínico, Universidad Nacional Autónoma de Nicaragua, León, Nicaragua

\* Autor para correspondencia.

Correo electrónico: williamwmorales@gmail.com (W. Morales).

<http://dx.doi.org/10.1016/j.riam.2016.06.006>

1130-1406/

© 2016 Asociación Española de Micología. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

## Rapid detection of *Cryptococcus gattii* sensu lato using gold nanoparticles



### Detección rápida de *Cryptococcus gattii* sensu lato mediante nanopartículas de oro

Dear Editor,

Successful treatment of cryptococcosis requires rapid, accurate identification of *Cryptococcus neoformans* or the *Cryptococcus gattii* species complex in addition to their discrimination from other pathogenic yeast species. Gold nanoparticles (AuNPs) have enabled improvements in biomedical sciences owing to their versatile properties and capacity for detecting biological molecules at low concentrations; these methods are inexpensive, rapid, and stable.<sup>1,2,6–9</sup> We describe the application of AuNPs for detecting *C. gattii* sensu lato.

Our protocol was approved by the Animal Research Ethics Committees (23108.014032/14-0) and Research Ethics Committees of Hospital Universitário Júlio Muller (888/CEP-HUJM/2010). Twenty-one clinical *C. gattii* sensu lato isolates and four *C. neoformans* sensu lato isolates from humans and animals were tested. DNA was extracted using the glass bead method<sup>3</sup> and samples representing each of the eight major molecular types of the *C. neoformans/gattii* species complex were used (Table 1). DNA samples from non-*Cryptococcus* microorganisms served as controls (Table 1).

AuNPs were synthesized using the citrate reduction method.<sup>4,5</sup> Briefly, 250 ml of 1 mM gold chloride was boiled and added to 25 ml of 38.8 mM sodium citrate. For the hybridization test, we used probes based on the superoxide dismutase (*SOD1*) gene of *C. gattii* sensu lato (*SOD1CGF* 5'-GATCCTCACGCCATTACG3' and *SOD1CGR* 5'-GAATGATGCGCTTAGTGGAA3'). First, 50 ng of sample DNA was denatured at 95 °C for 3 min in a mixture containing

1.25 M NaCl, 20 mM Tris–HCl, and 20 pmol oligonucleotides, followed by annealing at 50 °C for 2 min for hybridization and holding at 4 °C. This was followed by addition of 50 µl of the prepared AuNPs. Absorption (OD<sub>300</sub>–OD<sub>800</sub>) was measured using the BioTek® spectrophotometer (Winooski, VT, USA). The cutoff point was determined using the average absorbance values minus two standard deviations of five control samples without target DNA.

All reference samples were identified as *C. gattii* sensu lato, and a color change from red to purple indicated a positive reaction. Moreover, five non-*Cryptococcus* species and four *C. neoformans*

**Table 1**


Reference strains representing each of the eight major molecular types of the *Cryptococcus neoformans/gattii* complex, identified using amplified fragment length polymorphism (AFLP) and restriction fragment length polymorphism (RFLP), and non-*Cryptococcus* strains.

Reference strain/isolate	Genotype
<i>C. neoformans</i> sensu lato (WM148)	AFLP1/VNI
<i>C. neoformans</i> sensu lato (WM626)	AFLP1B/VNII
<i>C. neoformans</i> sensu lato (WM628)	AFLP3/VNIII
<i>C. neoformans</i> sensu lato (WM629)	AFLP3/VNIV
<i>C. gattii</i> sensu lato (WM179)	AFLP4/VGI
<i>C. gattii</i> sensu lato (WM178)	AFLP6/VGII
<i>C. gattii</i> sensu lato (WM161)	AFLP5/VGIII
<i>C. gattii</i> sensu lato (WM779)	AFLP7/VGIV
<i>Aspergillus fumigatus</i> (ATCC 204305)	NA <sup>a</sup>
<i>Pichia pastoris</i> (GS115)	NA <sup>a</sup>
<i>Conidiobolus lamprauges</i> <sup>b</sup> (INCQS 40316)	NA <sup>a</sup>
<i>Malassezia pachydermatitis</i> <sup>b</sup>	NA <sup>a</sup>
<i>Pythium insidiosum</i> <sup>c</sup> (CBS 101555)	NA <sup>a</sup>


<sup>a</sup> Not available.

<sup>b</sup> Internal transcribed spacer (ITS) sequenced.

<sup>c</sup> Stramenopila.



**Figure 1.** AuNPs test for detecting *C. gattii* based on the *sod* gene. VNI to VNIV: reference strains of *C. neoformans*; VGI to VGIV: reference strains of *C. gattii*. The reddish colour indicates a negative result, the purple one a positive result.



**Figure 2.** Graphic representation of the scanning absorbance of the standard positive strains of *C. gattii* and the standard negative strains of *C. neoformans*.

sensu lato isolates were subjected to the AuNP assay to evaluate its specificity. All results were negative with no cross-reaction (100% specificity, Fig. 1).

In the AuNP test of the reference *Cryptococcus* strains, there were spectrophotometric signals at the 525 and 655 nm absorbance peaks, indicating negative and positive results, respectively (Fig. 2). The average optical density at 525 nm for the positive reference samples was 0.28 (confidence interval [CI] = 0.27–0.30; SD = 0.009), and the average for the negative samples was 0.47 (CI = 0.39–0.52; SD = 0.05). These results established that a positive sample yields an OD<sub>525</sub> ≤ 0.37. Twenty-one (100%) clinical isolates of *C. gattii* sensu lato showed macroscopic positivity and OD<sub>525</sub> values between 0.24 and 0.30, i.e., below the cutoff value for a negative result.

In summary, AuNPs serve as an alternative tool for developing new methods for clinical diagnosis; our AuNP-based test allowed rapid and specific identification of *C. gattii* sensu lato isolates. Its main advantages are its simplicity, ease of use, and low cost for set up without the need for sophisticated equipment.

## Bibliografía

- Brandão LN, Pitchenin LC, Maruyama FH, Chitarra CS, Silva GFR, Klein C, et al. Padronização da técnica de nanopartícula de ouro não modificada (AuNPs) para detecção de *Actinobacillus pleuropneumoniae* em pulmões de suínos. *Pesq Vet Bras*. 2014;34:621–5.
  - Chandra P, Das D, Abdelwahab AA. Gold nanoparticles in molecular diagnostics and therapeutics. *Dig J Nanomater Biostuct*. 2010;5:363–7.
  - Del Poeta M, Toffaletti DL, Rude TH, Dykstra CC, Heitman J, Perfect JR. Topoisomerase I is essential in *Cryptococcus neoformans*: role in pathobiology and as an antifungal target. *Genetics*. 1999;152:167–78.
  - Freeman RG, Grabar KC, Allison KJ, Bright RM, Davis JA, Guthrie AP, et al. Self-assembled metal colloid monolayers: an approach to SERS substrates. *Science*. 1995;267:1629–32.
  - Grabar KC, Freeman RG, Hommer MB, Natan MJ. Preparation and characterization of Au colloid monolayers. *Anal Chem*. 1995;67:735–43.
  - Mieszawska AJ, Mulder WJM, Fayad ZA, Cormode DP. Multifunctional gold nanoparticles for diagnosis and therapy of disease. *Mol Pharm*. 2013;10: 831–47.
  - Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. *Nanomedicine*. 2012;8:147–66.
  - Valentini P, Pmpa PP. Gold nanoparticles for naked-eye DNA detection: smart designs for sensitive assays. *RSC Adv*. 2013;3:19181–90.
  - Wang EC, Wang AZ. Nanoparticles and their applications in cell and molecular biology. *Integr Biol (Camb)*. 2014;6:9–26.
- Fernanda H. Maruyama <sup>a,c</sup>, Daphne A.J. de Paula <sup>a,c</sup>,  
Olivia C. Favalessa <sup>b</sup>, Rosane C. Hahn <sup>b</sup>, Paula G. Cezarino <sup>c</sup>,  
Janaína M.A. Rosa <sup>a,c</sup>, Luciano Nakazato <sup>a,c,\*</sup>, Valéria Dutra <sup>a,c</sup>
- <sup>a</sup> Postgraduate Course in Veterinary Science, Department of Veterinary Science, Federal University of Mato Grosso, Cuiabá, Brazil  
<sup>b</sup> Postgraduate Course in Health Science, Federal University of Mato Grosso, Cuiabá, Brazil  
<sup>c</sup> Veterinary Hospital at UFMT, Cuiabá, Mato Grosso, Brazil
- \* Corresponding author.  
E-mail address: lucnak@ufmt.br (L. Nakazato).

<http://dx.doi.org/10.1016/j.riam.2016.07.001>

1130-1406/

© 2016 Asociación Española de Micología. Published by Elsevier España, S.L.U. All rights reserved.

## Querion de Celso de la vulva: una enfermedad común en una localización infrecuente



## Kerion of the vulva: A common pathology in an unusual location

Las dermatofitosis cutáneas son infecciones muy comunes producidas en la piel por un grupo de hongos denominados dermatofitos, conformado por los géneros *Trichophyton*, *Microsporum* y *Epidermophyton*, que afectan a las capas superficiales queratinizadas de la epidermis y anejos cutáneos<sup>8</sup>. Sin embargo, existen dermatofitosis denominadas profundas como el querion de Celso,

cuya localización más frecuente es el cuero cabelludo y se manifiesta clínicamente como una erupción pustulosa grave con intensa reacción inflamatoria y exudación purulenta<sup>8</sup>. A continuación describimos una localización atípica o poco frecuente de esta enfermedad.

Una mujer de 19 años de edad fue remitida a dermatología desde el servicio de ginecología por presentar lesiones pustulosas en la zona del pubis. La paciente había acudido en varias ocasiones a urgencias por el dolor local, donde se le había prescrito tratamiento antibiótico con amoxicilina-ácido clavulánico 875-125 mg/8 h/7 días y analgesia oral e intravenosa.